BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Reuters

22 Nov 2024

BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:

LEXICON TO REPOSITION AS CLINICAL DEVELOPMENT-FOCUSED COMPANY FOLLOWING REGULATORY UPDATE FROM FDA
LEXICON PHARMACEUTICALS INC: EFFORTS EXPECTED TO REDUCE 2025 OPERATING COSTS BY $100 MILLION
LEXICON PHARMACEUTICALS INC: PRIORITIZING STRONG RESEARCH AND DEVELOPMENT PIPELINE INCLUDING ONGOING STUDIES IN DPNP, HCM AND OBESITY
LEXICON PHARMACEUTICALS INC: IMPLEMENTING STRATEGIC RESTRUCTURING TO ELIMINATE COMMERCIAL ORGANIZATION AND RATIONALIZE OPERATIONS ACROSS ALL FUNCTIONS
LEXICON PHARMACEUTICALS INC: TOTAL REDUCTION OF APPROXIMATELY 60 PERCENT OF EMPLOYEES, EFFECTIVE FOR MOST AFFECTED EMPLOYEES BY DECEMBER 31
LEXICON PHARMACEUTICALS INC: ELIMINATION OF PROMOTIONAL EFFORTS FOR INPEFA, PLANNED COMMERCIAL ACTIVITIES FOR ZYNQUISTA
LEXICON PHARMACEUTICALS INC: RECEIPT OF A "DEFICIENCIES PRECLUDE DISCUSSION" LETTER FROM FDA REGARDING NDA FOR ZYNQUISTA

Source text: ID:nGNXnl2zP

Further company coverage: LXRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2485252504"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485252504\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485252504?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485252504","market":"us","top_or_hot":-1,"title":"BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA</title></head><body><p><span>Nov 22 (Reuters)</span><span> - </span>Lexicon Pharmaceuticals Inc <span>LXRX.O</span>:</p><ul><li><p>LEXICON TO REPOSITION AS CLINICAL DEVELOPMENT-FOCUSED COMPANY FOLLOWING REGULATORY UPDATE FROM FDA</p></li><li><p>LEXICON PHARMACEUTICALS INC: EFFORTS EXPECTED TO REDUCE 2025 OPERATING COSTS BY $100 MILLION</p></li><li><p>LEXICON PHARMACEUTICALS INC: PRIORITIZING STRONG RESEARCH AND DEVELOPMENT PIPELINE INCLUDING ONGOING STUDIES IN DPNP, HCM AND OBESITY</p></li><li><p>LEXICON PHARMACEUTICALS INC: IMPLEMENTING STRATEGIC RESTRUCTURING TO ELIMINATE COMMERCIAL ORGANIZATION AND RATIONALIZE OPERATIONS ACROSS ALL FUNCTIONS</p></li><li><p>LEXICON PHARMACEUTICALS INC: TOTAL REDUCTION OF APPROXIMATELY 60 PERCENT OF EMPLOYEES, EFFECTIVE FOR MOST AFFECTED EMPLOYEES BY DECEMBER 31</p></li><li><p>LEXICON PHARMACEUTICALS INC:  ELIMINATION OF PROMOTIONAL EFFORTS FOR INPEFA, PLANNED COMMERCIAL ACTIVITIES FOR ZYNQUISTA</p></li><li><p>LEXICON PHARMACEUTICALS INC:  RECEIPT OF A \"DEFICIENCIES PRECLUDE DISCUSSION\" LETTER FROM FDA REGARDING NDA FOR ZYNQUISTA</p></li></ul><p>Source text: <span>ID:nGNXnl2zP</span></p><p>Further company coverage: <span>LXRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-22 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA</title></head><body><p><span>Nov 22 (Reuters)</span><span> - </span>Lexicon Pharmaceuticals Inc <span>LXRX.O</span>:</p><ul><li><p>LEXICON TO REPOSITION AS CLINICAL DEVELOPMENT-FOCUSED COMPANY FOLLOWING REGULATORY UPDATE FROM FDA</p></li><li><p>LEXICON PHARMACEUTICALS INC: EFFORTS EXPECTED TO REDUCE 2025 OPERATING COSTS BY $100 MILLION</p></li><li><p>LEXICON PHARMACEUTICALS INC: PRIORITIZING STRONG RESEARCH AND DEVELOPMENT PIPELINE INCLUDING ONGOING STUDIES IN DPNP, HCM AND OBESITY</p></li><li><p>LEXICON PHARMACEUTICALS INC: IMPLEMENTING STRATEGIC RESTRUCTURING TO ELIMINATE COMMERCIAL ORGANIZATION AND RATIONALIZE OPERATIONS ACROSS ALL FUNCTIONS</p></li><li><p>LEXICON PHARMACEUTICALS INC: TOTAL REDUCTION OF APPROXIMATELY 60 PERCENT OF EMPLOYEES, EFFECTIVE FOR MOST AFFECTED EMPLOYEES BY DECEMBER 31</p></li><li><p>LEXICON PHARMACEUTICALS INC:  ELIMINATION OF PROMOTIONAL EFFORTS FOR INPEFA, PLANNED COMMERCIAL ACTIVITIES FOR ZYNQUISTA</p></li><li><p>LEXICON PHARMACEUTICALS INC:  RECEIPT OF A \"DEFICIENCIES PRECLUDE DISCUSSION\" LETTER FROM FDA REGARDING NDA FOR ZYNQUISTA</p></li></ul><p>Source text: <span>ID:nGNXnl2zP</span></p><p>Further company coverage: <span>LXRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LXRX","symbol_name":"莱斯康制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT104:1","article_id":"2485252504","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485252504","pubTimestamp":1732278999,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDANov 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:LEXICON TO REPOSITION AS CLINICAL DEVELOPM","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LXRX":"莱斯康制药","BK4139":"生物科技"},"translate_title":"根据FDA的监管更新，BRIEF-Lexicon将重新定位为专注于临床开发的公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXRX":0.9},"content_text":"BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDANov 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:LEXICON TO REPOSITION AS CLINICAL DEVELOPMENT-FOCUSED COMPANY FOLLOWING REGULATORY UPDATE FROM FDALEXICON PHARMACEUTICALS INC: EFFORTS EXPECTED TO REDUCE 2025 OPERATING COSTS BY $100 MILLIONLEXICON PHARMACEUTICALS INC: PRIORITIZING STRONG RESEARCH AND DEVELOPMENT PIPELINE INCLUDING ONGOING STUDIES IN DPNP, HCM AND OBESITYLEXICON PHARMACEUTICALS INC: IMPLEMENTING STRATEGIC RESTRUCTURING TO ELIMINATE COMMERCIAL ORGANIZATION AND RATIONALIZE OPERATIONS ACROSS ALL FUNCTIONSLEXICON PHARMACEUTICALS INC: TOTAL REDUCTION OF APPROXIMATELY 60 PERCENT OF EMPLOYEES, EFFECTIVE FOR MOST AFFECTED EMPLOYEES BY DECEMBER 31LEXICON PHARMACEUTICALS INC:  ELIMINATION OF PROMOTIONAL EFFORTS FOR INPEFA, PLANNED COMMERCIAL ACTIVITIES FOR ZYNQUISTALEXICON PHARMACEUTICALS INC:  RECEIPT OF A \"DEFICIENCIES PRECLUDE DISCUSSION\" LETTER FROM FDA REGARDING NDA FOR ZYNQUISTASource text: ID:nGNXnl2zPFurther company coverage: LXRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}